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Background/Aims  : Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma 
(AILT),  but  its  precise  role  and  prognostic  impact  are  not  clear.  This  study  aimed  to  evaluate  the  incidence  of 
EBV-postitivity in the tumor and bone marrow (BM) samples from  AILT patients, and their correlations with the clinical 
variables  and  patient  survival. 
Methods : Seventy  AILT  cases  were  identified  over  a  period  of  8  years.  Twenty  seven  cases  were  investigated  for 
their EBV tumor status, and 10 BM samples of these patients were investigated for their EBV status with using in situ 
h y b r i d i z a t i o n  ( I S H ) .  E B V  P C R  w a s  p e r f o r me d  f o r  t h e  B M mo n o n u c l ear  cells  in  8  cases. 
Results  :  Among  the  27  tumor  specimens,  ten  (37%)  were  EBV-positive.  Only  CD20-negativity  in  tumor  correlated 
wi t h t he EBV- pos i t i vi t y (p=0.035). In 13 (48%) patients, gross tumor involvement was recognized by  hematoxylin-eosin 
staining at the time of diagnosis. Among the 10 patients who had additional BM slides available, there were 3 with BM 
involvement,  and  none  showed  EBV  positive  results  on  ISH.  EBV  PCR  of  the  BM  mononuclear  cells  revealed 
one-positive  case  among  8  patients.  This  patient  was  negative  fo r  b o t h  B M  i n v o l v e m e n t  a n d  E B V  I S H .  T h e  m e d i a n  
overall  survival  of  the  25  treated  patients  was  48.9  months  (95%  CI:  18.6～79.2  months).  Neither  overall  survival  nor 
progression-free  survival  was  related  with  EBV-positivity  of  the  tumor. 
Conclusions  :  EBV-positivity  of  tumor  had  no  impact  on  the  prognosis  of  AILT  patients. 
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INTRODUCTION
More  than  90%  of  adults  worldwide  are  infected  with 
Epstein-Barr  virus ( E B V )  a n d  t h e y  c a r r y  t h e  v i r u s  a s  a  l i f e - l o n g  
p e r s i s t e n t  i n f e c t i o n ,  w i t h  l a t e n t  i n f e c t i o n  o f  t h e i r  B  l y m p h o c y tes 
and  viral  production  into  their  saliva
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the  pathogenesis  of  several  different  types  of  aggressive 
non-Hodgkin's  lymphoma  (NHL)  and  Hodgkin's  lymphoma.  In 
1976,  screening  27  cases  of  lymphoid  tissue  lesions  for 
EBV-DNA  with  using  nucleic  acid  reassociation  kinetics  led  to 
the  detection  of  one  virus-positive  case  of  angioimmunoblastic 
T-cell  lymphoma  (AILT)
3).
  Many  subsequent  studies  have 
demonstrated the presence of EBV in 58～97% of all AILT cases 
in  either  the  T  or  B  cells
4-7). The clinical presentation of AILT is 
usually  systemic  disease  with  B  symptoms,  while  the  pathology 
reveals a polymorphous infiltrate involving the lymph nodes with 
a  prominent  proliferation  of  endothelial  and  dendritic  cells
8). 
Some patients go on to develop a secondary EBV- positive large 
B-cell  lymphoma. 
  A recent study demonstrated that the presence of EBV-DNA 
obtained by performing real-time quantitative PCR and Southern 
blotting analysis of tumor tissue had no significant effect on the 
clinical outcome of AILT patients
9).
  As for the patients with nasal 
NK/T-cell  lymphoma,  a  EBV-positive  tumor  is  a  prerequisite  for 
making the diagnosis
10). A recent study proved that minimal EBV 
involvement in the bone marrow (BM) was a powerful prognostic 
marker
11). 
Therefore,  we  performed  this  study  to  evaluate  the  rate  of 
E B V - p o s i t i v i t y  i n  t u m o r  a n d  B M  a n d  t h e i r  p r o g n o s t i c  v a l u e s  f o r  
the  clinical  outcome  of  AILT  patients. 
MATERIALS AND METHODS
Patients
Over a period of 8 years (from August 1998 to July 2005), 70 
AILT cases from 8 medical centers were identified based on the 
histological  and  immunohistochemical  criteria  with  using  the 
REAL and/or WHO classifications. We enrolled 27 patients who 
had  additional  tissue  slides  for  EBV  in  situ  hybridization  (ISH). 
T e n  p a t i e n t s '  B M s l i d e s  w e r e  a l s o  a n a l y z e d  i n  t h i s  s t u d y .  E i g h t 
patients  had  their  cryopreserved  BM  mononuclear  cells  for 
p e r f o r mi n g  E B V  D N A  P C R .
All  the  patients  were  staged  according  to  the  Ann  Arbor 
staging  system.  The  complete  staging  procedures  included 
physical  examination,  chest  X-ray,  complete  blood  cell  counts, 
blood  biochemistry,  computed  tomography  of  the  thorax, 
abdomen and pelvis, and BM aspiration and biopsy. The clinical 
and  laboratory  records  were  reviewed  for  all  the  patients.
Treatment
The  chemotherapy  regimens  included  CHOP  (cyclophospha-
mide,  Hydroxydaunomycin,  vincristin  and  prednisone),  CHOP-E 
(etoposide)  or  ESHAP  (etoposide,  solumedrol,  cytarabine  and 
cisplatin).
ISH  for  EBV  in  the  tumor  and  BM  biopsy
12)
We performed EBV ISH on 27 tumor specimens and 10 BM 
biopsy specimens. The paraffin-embedded sections of the biopsy 
specimens  were  deparaffinized  with  xylene,  and  this  was 
followed by treatment with proteinase K. The sections were then 
hybridized  with  fluorescein  isothiocynanate-conjugeted  EBV 
oligonucleotides  (Novocastra,  Newcastle,  U.K.)  that  were 
complementary  to  the  nuclear  RNA  protein  of  the  EBER1  and 
EBER2 genes. Positive labeling was identified only when the cells 
showed  nuclear  staining  with  EBV  oligonucleotide.  As  negative 
controls,  we  used  EBV  negative  lymphoid  tissues  and  a 
hybridization  mixture  without  the  EBV  oligonucleotides.  As  the 
internal positive control, the tumor and BM slides of patient with 
NK-cell  leukemia  were  used.
S a m p l e  D N A  p r e p a r a t i o n  a n d  E B V  P C R
11)
The  BM  mononuclear  cells  from  8  patients  were  studied  by 
performing  EBV  PCR.  EBV  DNA  was  extracted  from  the 
patients'  BM  aspiration  samples  (frozen  monocytes)  with  using 
the  QIAmp  DNA  Blood  Mini  Kit  (Qiagen,  USA).  Approximately 
100ng  of  DNA  was  used  for  PCR  reaction.  The  PCR  primer 
sequences  were  5'-GACGAGGGGCCAGGTACAGG-3'  and 
3'-GCAGCCAATGCAACTTGGACGTTTTAGG-5', respectively. The 
PCR  reaction  was  performed  using  the  primer  set  (Maxim 
b i o t e c h ,  I n c ,  U S A ) .  T h e  P C R  mi x t u r e  c on t a i n e d  2 50  μL  o f  t h e  
pre-mixed  primers  and  750  μL  of  optimized  PCR  buffer.  The 
PCR  was  preformed  in  a  total  volume  of  50  μL,  which 
contained 10.0 L of DNA, 39.8 L of the PCR mixture and 0.2 μ
L  of  Taq  DNA  polymerase.  The  amplification  reaction  was 
p e r f o r m e d  f o r  3 7  c y c l e s  u n d e r  t h e  f o l l o w i n g  c o n d i t i o n s :  i n i t i a l ly, 
9 6 ℃  f o r  1 m i n  f o r  a c t i v a t i o n  ( o n e  c y c l e ) ,  f o l l o w e d  b y  a  
denaturation  phase  at  94℃  for  1min,  an  annealing  phase  at  5
8℃ for 1min and an extension phase at 72℃ for 1min (35 cycles). 
Another 10 min extensi on phase at 72℃ was performed at the 
end of each round of PCR. Ten microliters of the PCR products 
were  subjected  to  electrophoresis  (100V,  25min)  on  a  2% 
agarose  gel,  and  the  products  were  stained  with  ethidium 
bromide. The presence or absence of specific PCR targets was 
observed  under  UV  illumination.
Statistical  analysis
Overall  survival  was  measured  from  the  time  of  diagnosis  to 
death  or  to  the  last  follow-up.  The  survival  curves  were 
calculated  using  the  Kaplan-Meier  method  and  they  were  then 
compared  using  the  log-rank  test.  Other  clinical  factors  were 
compared  using  chi-square  tests  or  t-tests.  Differences  were 
considered  statistically  significant  if  the  p  value  was  <0.05.  All 
statistical analyses were performed using the SPSS for Windows 
13.0  statistical  package  (SPSS  Inc.,  Chicago,  IL).The  Korean  Journal  of  Internal  Medicine  :  Vol.  23,  No.  1,  March  2008 32
Case  No Age(yr)/Gender Initial  stage
CD  20  in 
tumor
EBV  ISH  in 
tumor
BM  invasion  at 
diagnosis
IPI
Survival
(months)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
54/M
49/M
66/M
50/M
52/F
57/M
54/M
62/F
38/M
17/F
57/F
31/F
68/M
51/M
53/M
64/M
42/M
75/M
27/F
58/M
67/M
71/M
66/M
64/F
71/M
63/F
74/M
4A
3A
4A
4A
3B
4B
3A
4B
4B
4B
3B
4B
4B
3B
3B
4B
4B
3B
4B
4B
4A
4A
4B
4AE
3B
4BE
none
-
+
-
-
-
-
-
-
-
-
NE
-
-
-
-
+
-
NE
+
+
-
-
-
-
+
+
-
-
-
+
+
-
+
+
+
-
-
-
-
+
-
+
-
-
-
-
-
+
+
+
-
-
-
-
+
-
+
+
-
-
-
-
-
+
-
+
+
-
-
+
-
-
+
+
+
+
+
+
-
-
NE
2
1
3
4
2
3
1
4
2
3
4
3
5
2
3
3
4
4
4
3
2
4
3
4
4
4
NE
A  (6.6)
A  (1.2)
A  (20.7)
A  (13.3)
A  (2.5)
D  (1.7)
D  (12.4)
A  (11.9)
D  (11.7)
A  (75.6)
D  (50.7)
A  (21.5)
D  (0.5)
D  (48.9)
A  (35.5)
D  (23.7)
D  (5.3)
D  (2.3)
A  (37.8)
A  (36.3)
A  (13.3)
D  (3.1)
A  (36.8)
A  (0.3)
D  (21.4)
D  (2.8)
D  (0.5)
NE,  not  evaluated;  A,  alive;  D,  death.
Table  1.  Clinicopathologic  findings  of  the  27  patients  with  angioimmunoblastic  T-cell  lymphoma
RESULTS
Clinical  features
One  patient  among  the  27  AILT  patients  refused  any  further 
staging  work-up.  The  clinicopathologic  data  of  the  27  patients 
are summarized in Table 1. This series included 19 men and 8 
women with ages from 17 to 75 (median age: 57 years-old). All 
the patients except one had stage III or IV disease. Anemia was 
detected  at  diagnosis  in  10  patients;  two  of  them  had 
autoimmune  hemolytic  anemia.  Twenty  five  patients  received 
chemotherapy,  including  23  patients  who  received  CHOP,  1 
patient  who  received  CHOP-E  and  1  patient  who  received 
ESHAP,  while  2  patients  received  only  supportive  care. 
EBV  ISH  in  the  tumor  and  its  clinical  impact 
Among the tumor specimens obtained at the time of the initial 
diagnosis  from  the  27  AILT  patients,  10  were  positive  for  EBV 
I S H .  T h e  c o r r e l a t i o n s  o f  t h e  c l i n i c a l  s t a t u s ,  s u c h  a s  t h e  
i n t e r n a t i o n a l  p r o g n o s t i c  i n d e x  ( I P I )  s c o r e ,  a g e ,  s t a g e  a n d  o t h e r 
laboratory  findings,  with  the  EBV  status  of  tumor  are 
summar i zed i n Tabl e 2.  Onl y CD20 negat i vi t y i n t he t umor  was 
significant  correlated  with  EBV-positivity  in  the  tumor  (p=0.035). 
The  median  overall  survival  and  progression-free  survival  of 
the 25 treated patients were 48.9 months (95% CI: 18.6～79.2 
months) and 32.3 months (95% CI: 11.5～53.1 months) (Figure 
1A).  There  were  no  significant  correlations  between  EBV- 
positivity  in  tumor  and  the  overall  or  progression-free  survival. 
BM  involvement  by  Hematoxylin-eosin  staining,  ISH  or  PCR
In  13  of  the  26  AILT  patients,  gross  tumor  involvement  was 
recognized in the initial BM sample by hematoxylin-eosin staining 
( H - E  s t a i n ) .  N o n e  o f  t h e  1 0  p a t i e n t s  w h o  h a d  a d d i t i o n a l  B M  
slides available revealed EBV-positivity on BM ISH. Among these 
10 patients, 3 patients showed BM involvement by H-E staining, 
b u t  t h i s  w a s  n o t  i d e n t i f i e d  o n  E B V  I S H  ( F i g u r e  2 )  o r  P C R .  Y e t  
one  patient  among  the  5  patients  without  BM  involvement 
showed a positive band on PCR (Figure 3). BM involvement by 
H-E  staining  was  not  related  with  the  clinical  status  as  defined 
by  the  IPI,  age,  stage  and  laboratory  findings  (Table  3).  The 
overall  survival  and  progression-free  survival  for  the  treated 
patients among the 13 patients with BM involvement, according 
to H-E staining, were longer than those for the patients without Yuna  Lee,  et  al  :  Epstein-Barr  virus  and  angioimmunoblastic  T-cell  lymphoma 33
Variables Category EBV  ISH‐positive  EBV  ISH‐negative p v a l u e
Age
H&N  LN
CD20
Hemoglobin
WBC
LDH
stage
PS
B  symptom
≤  60  yrs
>  60  yrs
mean
not  involved
involved
Positive
Negative
≥10
<10
mean
≤10K
>10K
≤  UNL
>  UNL
mean
I-II
III-IV
0～1
2～4
no
Yes
4
6
61.4
0
10
0
10
7
3
11.0
8
2
5
5
495
0
10
5
5
5
5
11
6
52.2
4
13
6
9
9
8
10.3
12
5
3
13
662
1
16
8
9
3
14
0.212
0.112
0.097
0.035
0.384
0.590
0.093
0.434
0.883
0.075
Table  2.  C o r r e l a t i o n  b e t w e e n  t u m o r  E B V  p o s i t i v i t y  o n  I S H  a n d  t h e  c l i n i c o -laboratory  findings
Figure  1.  Kaplan-Meier  curves  for  overall  (solid 
line) and progression free survival (dotted line) for 
the  25  treated  patients  with  angioimmunoblastic 
T-cell  lymphoma  (A).  Comparison  of  the  overall 
s u r v i v a l  ( B )  a n d  p r o g r e s s i o n - f r e e  s u r v i v a l  ( C )  
between  the  patients  with  bone  marrow 
involvement  (solid  line)  and  those  without  BM 
involvement  (dotted  line)
BM involvement (p=0.054 and p=0.005, respectively; Figure 1B, 
1C). 
Clinical  factors  affecting  survivals
On  univariate  analysis,  older  age,  male  gender,  pulmonary 
parenchymal  involvement,  the  presence  of  edema  and  negative 
BM were adverse factors for progression-free survival and overall 
survival.  Male  gender  (p=0.041),  pulmonary  parenchymal 
involvement (p=0.039) and negative BM (p=0.042) all significantly 
shortened  the  progression-free  survival  on  multivariate  analysis. 
Among  the  significant  factors  for  overall  survival,  male  gender 
(p=0.078),  pulmonary  parenchymal  involvement  (p=0.044)  and 
A B
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Variables Category BM  involvement  No  BM  involvement p  value
Age 
H&N  LN
CD20
Hemoglobin
WBC
LDH
PS
B  symptom
≤  60  yrs
>  60  yrs
mean
not  involved
involved
Positive
Negative
≥10
<10
mean
≤10K
>10K
≤  UNL
>  UNL
mean
0～1
2～4
no
Yes
6
7
54.1
1
12
3
10
6
7
9.96
9
4
4
9
631.2
7
6
6
7
9
4
55.7
3
10
3
8
10
3
11.45
11
2
4
9
565.5
6
7
2
11
0.234
0.780
0.277
0.329
0.107
0.352
1.000
0.695
0.089
Table  3.  Correlation  between  BM  involvement  and  the  clinicolaboratory  findings
  
Figure 2. In situ hybridization for EBV in the bone marrow biopsies. Positive staining for EBV in a case with NK/T-cell leukemia (A), and negative 
staining  in  a  patient  with  angioimmunoblastic  T-cell  lymphoma  (B)
negative  BM  (p=0.080)  also  had  modest  significance  on 
multivariate  analysis.
DISCUSSION
EBV DNA was detected in Burkitt's lymphoma tissue in 1964, 
f r o m  n o n - H o d g k i n ' s  l y m p h o m a  i n  t h e  e a r l y  1 9 8 0 s  a n d  f r o m  
T - c e l l  l y m p h o ma  a n d  H o d g k i n ' s  l y mp h o ma  i n  t h e  l a t e  1 9 8 0 s
13). 
Clonotypic  proliferation  of  EBV  has  been  demonstrated  in  the 
neoplastic  cells  of  lymphoid  malignancies,  which  suggests  a 
causative role for EBV in their tumorigenesis
14). The cells infected 
w i t h  E B V  a r e  t h o u g h t  t o  a v o i d  a p o p t o s i s  b y  e x p r e s s i n g  E B V  
l a t e n t  m e m b r a n e  p r o t e i n s  ( L M P )  1  ( C D  4 0  h o m o l o g u e )  a n d  2 a  
(BCR  engagement). Infected B  cells are delivered  by binding  to 
helper T cells via the CD40 molecule that presents on the B cell 
surface, and by binding to the B cell receptor
1). The outcome of 
AILT  is  poor,  with  most  series  reporting  a  5-year  OS  of 
approximately 30%  and  a  median survival of  3  years
15).  Several 
studies have been done to assess how the pathogenesis of EBV 
contributes  to  the  prognosis.  Anagonostopoulos  et  al
7) s h o w e d  
the predominant infection of B cells in the nodular EBV-positive 
cases  and  the  predominant  infection  of  T  cells  in  the  diffusely 
EBV-positive  cases,  and  this  was  confirmed  by  double  labeling 
for EBER and the lineage markers for all the AILT cases. Further, 
EBV infection of the two cell lineages would appear to be unique 
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Figure  3.  PCR  analysis  showed  the  EBV-specific  DNA  sequences.  The 
EBV  DNA  was  detected  in  the  BM  mononuclear  cells  of  one  patient 
( w h i t e  a r r o w  i n  l i n e  8 ) .  L i n e s  1 ～ 8  a r e  f o r  t h e  B M  s a m p l e s  o f  t h e 
angioimmunoblastic T-cell lymphoma cases, lines 9～10 are for the BM 
samples  of  NK/T-cell  lymphoma  cases,  and  line  11  is  for  the  positive 
control  in  the  EBV  PCR  kit  (240  base  pairs)
to AILT as this has not yet been reported for other malignancies, 
but  the  pathway  of  B-  and  T-cell  infection  by  EBV  in  AILT 
patients is unclear. Our study showed that CD20 negativity of a 
tumor  was  significant  correlated  with  EBV  ISH  positivity 
(p=0.035).The  expression  of  the  CD20  antigen  may  be  down 
regulated  in  latently  EBV-infected  small  lymphoid  cells  in  vivo
16). 
Our  findings  supported  this  observation.  Several  other  articles 
showed  the  contradictory  result  that  AILT  often  have  increased 
numbers  of  CD20-positive  cells  that  are  also  EBV-positive
17-19). 
This  discrepancy  needs  further  verification.  The  relative  lower 
incidence  (37%)  of  EBV-positivity  of  tumor  in  this  study  was 
lower when compared to that (58～97%) of western studies. We 
used an adequate positive control, that is, EBV-positive NK/T-cell 
leukemia. Therefore, using more sensitive methods such as PCR 
to detect low copy numbers of EBV would be the next step
9, 20). 
Another aim of this study was to adopt the prognostic model 
of  minimal  BM  involvement  by  EBV-positive  tumor  cells  in 
NK/T-cell  lymphoma  and  apply  it  to  AILT.  Unexpectedly,  it  was 
difficult to use EBV ISH or PCR for detecting EBV-positive tumor 
cells in BM, such as those EBV-positive tumor cells in NK/T-cell 
lymphoma. The EBV ISH or PCR results were all negative for the 
A I L T  p a t i e n t s  w i t h  g r o s s  t u m o r  i n v o l v e m e n t ,  a s  d e t e r m i n e d  b y  
H-E  staining.  This  made  it  impossible  to  introduce  the  concept 
of minimal BM involvement by EBV-positive tumor cells in AILT. 
Also, the results of performing EBV ISH and/or PCR for tumor or 
BM had no impact on the outcomes of the AILT patients in our 
study;  this  was  similar  to  a  recent  Japanese  study
9). 
Our  study  showed  a  particular  result  that  the  overall  survival 
and  progression  free  survival  of  the  AITL  patients  with  BM 
involvement  were  significant  longer  than  those  of  the  patients 
without  BM  involvement.  Of  course,  the  limited  number  of 
patients  makes  it  difficult  to  generalize  this  finding.  However, 
most AILT patients  in this  study were at  an  advanced  stage of 
disease  at  the  time  of  diagnosis.  Except  for  stage,  patient 
survival  was  significantly  related  to  age,  B  cell  symptoms, 
rash/pruritus,  edema,  ascites,  lactate  dehydrogenase, 
hemoglobin and the number of clinical symptoms with excluding 
the  B  symptoms  of  the  AILT  patients
21).  The  presence  of  bulky 
disease  (>7.5  cm),  an  advanced  stage  and  bone  marrow 
involvement did not influence survival of the patients with T-cell 
lymphoma  in  the  previous  studies
22, 23).  Unlike  B-cell  lymphoid 
malignancies such as diffuse large B-cell lymphoma and chronic 
lymphoid  leukemia,  BM  involvement  may  not  be  a  poor 
prognostic factor for T-cell lymphoma. A future study that would 
include  a  sufficient  number  of  AILT  patients  will  clarify  this 
particular  finding. 
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